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Abstract 
Activated granulocytes, monocytes, and platelets appear to be closely involved in active 
Crohn’s disease (CD). Adsorptive granulocyte apheresis (GCAP) is a new treatment for 
inflammatory bowel disease. GCAP was used to treat a 23-year-old female patient with 
CD resistant to both infliximab (IFX) and azathioprine (AZA). At 16 years of age, the 
patient underwent a partial ileal resection for peritonitis caused by perforative ileitis. On 
pathological examination of the resected specimen, the diagnosis was CD. Mesalazine was 
started, but the patient did not comply with therapy. She was admitted to our hospital again 
in 2007 due to an acute exacerbation. IFX induction therapy was started. The combination of 
both AZA daily and IFX every 8 weeks was continued as maintenance therapy. However, she 
developed severe abdominal pain in September 2009. Computed tomography revealed ileitis 
and ascending colitis, and blood tests showed high inflammatory response marker levels. 
She was considered to have IFX- and AZA-resistant CD. Initial intravenous steroid therapy did 
not result in any improvement. Therefore, weekly GCAP therapy was given for 5 weeks, 
which immediately improved the inflammatory response markers. GCAP combined with 
prednisolone could be effective for IFX- and AZA-refractory CD. 
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Introduction 
Inflammatory bowel disease (IBD) comprises a group of cryptogenic diseases of 
the intestine with long-standing chronic inflammation characterized by repeated 
exacerbations and remissions. Steroid treatment is still a cornerstone of medical 
treatment for IBD, such as ulcerative colitis and Crohn’s disease (CD). Unfortunately, 
IBD patients who are treated with steroids sometimes develop steroid-dependent or 
steroid-resistant conditions. Immunosuppressants, such as azathioprine (AZA) and 
6-mercaptopurine, and new biological drugs, such as infliximab (IFX), are considered 
effective treatments in inducing disease remission and steroid-free clinical remission. 
Although these medications are key treatments for IBD, some patients are refractory or 
intolerant to them, and it is very difficult to control their disease activity. Activated 
granulocytes, monocytes, and platelets are known to play important roles in active IBD. 
Adsorptive granulocyte apheresis (GCAP) to reduce the level of activated peripheral 
blood leukocytes in patients with ulcerative colitis has significant clinical efficacy and 
suppresses pro-inflammatory cytokines produced by peripheral blood leukocytes. 
These actions should directly reduce leukocytes and granulocytes related to 
inflammation and induce remission in patients with active CD. Some investigators have 
postulated that GCAP therapy might be effective for inducing remission and for treating 
patients with refractory CD. Therefore, GCAP and steroid combination therapy was 
tried in the following CD case who was refractory to IFX and AZA. 
Case Report 
A 23-year-old woman with CD was admitted to our hospital for the treatment of lower abdominal 
pain. At the age of 16 years, she underwent an ileo-cecal resection because of peritonitis caused by 
perforation thought to be due to acute appendicitis. CD was finally diagnosed based on the presence 
of the pathological characteristics of CD in the resected intestine. Mesalazine was started for the CD, 
but the patient did not comply with this therapy. She was admitted to our hospital again in 2007 
(5 years after her last examination) due to an acute exacerbation. Three infusions of IFX (5 mg/kg) 
were administered as induction therapy, and further doses were repeated every 8 weeks as 
maintenance therapy. However, she had severe abdominal pain and frequent diarrhea again in 
February 2009, which was thought to be an acute exacerbation of CD based on physical examination 
and laboratory data. Initially, the interval of IFX administration was shortened from 8 to 6 weeks, and 
she recovered from these symptoms. Three months later, she had occasional abdominal pain again, 
and she was thought to have developed tachyphylaxis to IFX; therefore, an immunosuppressant (AZA 
0.5 mg/kg) was started. Unfortunately, severe abdominal pain developed again in September 2009. 
Non-enhanced abdominal computed tomography (CT) showed marked wall thickness and fluid 
collection in the anastomosis (fig. 1). Blood examination also disclosed high inflammatory response 
marker levels (erythrocyte sedimentation rate [ESR] 37 mm/h, C-reactive protein [CRP] 4.23 mg/dl). 
The CD activity index (CDAI) had also increased to 255. 
Oral intake was stopped, and intravenous hyperalimentation was given from the start of 
admission. Intravenous prednisolone (40 mg/day, 0.8 mg/kg) was also infused because her CD was 
considered to be severely active. However, her condition did not respond to intensive steroid therapy 
for 1 week. Weekly GCAP therapy was then given for 5 weeks. Once GCAP therapy was started, her 
inflammatory response marker levels immediately and completely improved (CRP 0.22 mg/dl, ESR 
9 mm/h; CDAI 21). Abdominal CT, which was performed 1 week after the second GCAP, also showed 
marked improvement of wall thickness and fluid collection in the anastomosis. To evaluate the 
intestinal mucosal healing, balloon enteroscopy was performed after the third GCAP. The enteroscopic 
findings showed destroyed ileo-cecal valves, despite the absence of active ulcers or erosions (fig. 2). A 
fibrous stricture of the anastomosis was considered to be a non-responsive lesion to the steroid and  
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GCAP treatment. Therefore, an ileo-cecal resection was performed to remove this stricture. Since the 
operation, she has been well. 
Discussion 
IFX is considered to be a key therapy for inducing and maintaining remission in 
patients with CD [1, 2]. Regularly scheduled IFX therapy for CD consists of 3 infusions 
of IFX (5 mg/kg) to induce remission, and further doses are repeated every 8 weeks 
[2]. High-dose IFX therapy or a shorter period of scheduled IFX therapy is sometimes 
required when the effects of IFX are weakened because of the development of 
antibodies to IFX. Immunosuppressants such as AZA and 6-mercaptopurine are also 
widely used as CD maintenance therapy. Recently, the SONIC study reported that IFX 
and AZA combination therapy induced higher rates of corticosteroid-free clinical 
remission and mucosal healing compared to IFX monotherapy or AZA monotherapy [3]. 
This case maintained remission with IFX therapy initially, but then developed frequent 
diarrhea and abdominal pain despite receiving IFX every 8 weeks as maintenance 
therapy. The addition of an immunosuppressant to IFX was not effective for her acute 
exacerbation. Although intravenous prednisolone had been administered for 1 week to 
relieve her symptoms, she showed no evidence of recovery. Therefore, another therapy 
was needed to control her inflammatory reaction. We decided to use GCAP therapy 
because it has been reported to be a novel therapy for CD that can reduce the 
inflammatory response. From the start of GCAP therapy, her symptoms and 
inflammatory response immediately and completely improved. Abdominal CT, which 
was performed 1 week after the second GCAP, also showed marked improvement of 
wall thickness and fluid collection in the anastomosis. The balloon enteroscopy 
performed 1 week after the third GCAP also disclosed no active ulcers or erosions other 
than the destroyed ileo-cecal valves. The patient’s clinical course is summarized in 
fig. 3. 
In general, active CD lesions involve activated granulocytes, monocytes, and 
platelets. GCAP is an extracorporeal apheresis technique in which a specialized column 
selectively traps peripheral activated granulocytes and monocytes [1]. This therapy is 
expected to suppress and stop the immunological response in the active phase, as in an 
acute exacerbation. GCAP is a novel therapy for IBD, and it was first reported by 
Shimoyama et al. in 2001 [1]. GCAP is performed with a unique immuno-adsorption 
column, Adacolumn® (Japan Immuno-Research Co. Ltd., Gunma, Japan). The 
Adacolumn® has a capacity of 335 ml, filled with 220 g of 2 mm diameter cellulose 
acetate beads as the column adsorptive carriers. The carriers adsorb about 65% of 
granulocytes, 55% of monocytes, and a small fraction of lymphocytes (FcγR and 
complement receptor-bearing leucocytes) [4]. GCAP therapy obviously suppresses the 
production of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-8) by circulating 
peripheral blood leucocytes [1]. GCAP therapy was well tolerated, and no severe side 
effects were reported [4–10]. Recently, some investigators have postulated that 
patients with refractory CD might respond to a reduction of granulocytes and 
monocytes with GCAP. Both Kusaka et al. [7] and Fukuda et al. [6] reported in 2004 
that GCAP is effective for inducing remission and improving quality of life in patients 
with active CD that is refractory to conventional therapies such as mesalamine, 
prednisolone, metronidazole, and nutritional therapy. Fukuda et al. [6] also reported  
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that 11 of 21 active CD patients (52.4%) responded to GCAP, 6 with clinical remission 
and 5 with significant improvement. At present in Japan, GCAP therapy for CD is 
performed as 5 apheresis treatments over 5 weeks (once a week). Some papers have 
also reported that GCAP is effective for patients with rheumatoid arthritis [11], 
pyoderma gangrenosum [12], pustular psoriasis [13], and severe alcoholic hepatitis. 
In the present case, prednisolone therapy did not completely relieve the patient’s 
symptoms, but levels of inflammatory response markers, such as CRP, ESR and CDAI, 
were partially improved. On the other hand, her clinical findings and CT findings 
immediately improved when GCAP therapy was combined with prednisolone therapy. 
Therefore, we consider that, except for a fibrous stricture, GCAP and prednisolone 
combination therapy was an effective treatment for active CD in our patient. GCAP 
combined with prednisolone could be effective for IFX- and AZA-refractory CD. 
Disclosure Statement 
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Fig. 1. Non-enhanced abdominal CT on admission showed marked wall thickness and fluid collection 
in the anastomosis. 
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Fig. 2. Balloon enteroscopy was performed 1 week after the third GCAP therapy to evaluate intestinal 
mucosal healing. It showed no active ulcers or erosions, except for the destroyed ileo-cecal valves. 
 
 
 
Fig. 3. Clinical course. 
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